BioSpace News Archive

Co-Diagnostics, Inc. announced that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock.

Burning Rock Biotech Limited announced that the National Medical Products Administration approved Burning Rock’s Human Nine-Gene Mutation Joint Detection Kit as a class III medical device.

Saladax Biomedical, Inc. (Saladax) is pleased to announce the signing of a global distribution agreement with Beckman Coulter, Inc. to distribute the MyCare™ Psychiatry Laboratory Assays. The MyCare™ Psychiatry Laboratory Assays measure drug levels of the antipsychotic drugs prescribed to treat patients with serious mental illness (SMI), such as such as Schizophrenia and Bipolar Disorder.

Ms. Westby will leverage her extensive business and legal experience in international agriculture, specifically around commercial arrangements, strategy and intellectual property.

Answering the call for real-world data on the clinical and economic outcomes of pharmacogenomics and comprehensive medication management, Coriell Life Sciences – an international leader in precision medicine – has released new research on the impact of these tools at scale.

Temedica GmbH, a leading digital health and health insights company, today announced its cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis.

SiSaf Ltd, a company developing RNA therapeutics for rare genetic skeletal disorders, is pleased to confirm that it will be presenting at and attending a number of upcoming business, partnering and scientific conferences, as detailed below.

According to Precedence Research, the global teledermatology market size is expected to hit US$ 67.43 billion by 2030 from valued at US$ 12.70 billion in 2021, growing at a CAGR of 20.4%.

According to Precedence Research, the preterm birth and PROM testing market size is predicted to reach over US$ 2.21 billion by 2030 and growing at a CAGR of 3.2% from 2022 to 2030.

The pharmacovigilance market size is expected to hit US$ 16.23 billion by 2030 and expanding growth at a CAGR of 7.5% from 2021 to 2030.